IMPROVEMENT IN PATIENTS WITH COMORBIDITIES

Co-primary endpoint: LS mean* change from baseline in nasal obstruction score† during Weeks 49-52 (total population). NUCALA + SOC, –4.40 vs placebo + SOC, –2.54; P<0.001.1,2

Reduction in nasal obstruction in patients with comorbidities

Subgroup analysis graph of LS mean change from baseline in nasal obstruction score at Weeks 49-52 in two subgroups of patients with comorbid asthma and comorbid AERD showing a reduction in nasal obstruction score Subgroup analysis graph of LS mean change from baseline in nasal obstruction score at Weeks 49-52 in two subgroups of patients with comorbid asthma and comorbid AERD showing a reduction in nasal obstruction score

*LS means from an analysis using mixed model repeated measures.

†Symptom severity measured on patient-reported VAS from 0 (none) to 10 (as bad as you can imagine).

‡Also known as NERD.

SYNAPSE study design

Request a rep

Want to know more?

Request a rep

Improvement in asthma control in CRSwNP patients with comorbid asthma2

Subgroup analysis graph of LS mean improvement from baseline over a 52 week time period for the placebo and NUCALA showing the improvement in asthma control in patients with comorbid asthma Subgroup analysis graph of LS mean improvement from baseline over a 52 week time period for the placebo and NUCALA showing the improvement in asthma control in patients with comorbid asthma
57% of patients had a clinically important difference on NUCALA vs 35% on placebo at Week 52 infographic

§Scores on the ACQ range from 0 to 6 with higher scores indicating worse control.
llLS means from analysis using mixed model repeated measures.
Defined as improvement in ACQ-5 total score of ≥0.5 points from baseline for MCID.

SYNAPSE study design

Meta-analysis: severe eosinophilic asthma

See asthma exacerbation data by nasal polyps

EXPLORE THE DATA

NUCALA is for the add-on treatment of patients 6+ with severe eosinophilic asthma. Not for acute bronchospasm or status asthmaticus.

ACQ-5=Asthma Control Questionnaire (5-item); AERD=aspirin-exacerbated respiratory disease; CI=confidence interval; LS=least squares; MCID=minimum clinically important difference; NERD=nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease; OR=odds ratio; SOC=standard of care; VAS=visual analog scale.

NUCALA Prescription

Navigate a NUCALA prescription

Get patients started